Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, Ibrahim JG, Bixby L, Reisdorf S, Laurie SJ, Park YA, Anders CK, Collichio FA, Muss HB, Carey LA, van Deventer HW, Dees EC, Serody JS. Vincent BG, et al. Among authors: collichio fa. J Immunol. 2023 Jul 15;211(2):219-228. doi: 10.4049/jimmunol.2300077. J Immunol. 2023. PMID: 37204246 Free PMC article. Clinical Trial.
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Chesney JA, et al. Among authors: collichio fa. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. J Immunother Cancer. 2023. PMID: 37142291 Free PMC article. Clinical Trial.
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.
Oldan JD, Giglio BC, Smith E, Zhao W, Bouchard DM, Ivanovic M, Lee YZ, Collichio FA, Meyers MO, Wallack DE, Abernethy-Leinwand A, Long PK, Trembath DG, Googe PB, Kowalski MH, Ivanova A, Ezzell JA, Nikolaishvili-Feinberg N, Thomas NE, Wong TZ, Ollila DW, Li Z, Moschos SJ. Oldan JD, et al. Among authors: collichio fa. Oncoimmunology. 2023 Apr 26;12(1):2204753. doi: 10.1080/2162402X.2023.2204753. eCollection 2023. Oncoimmunology. 2023. PMID: 37123046 Free PMC article.
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, van Akkooi A, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, Bagge RO, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. Eroglu Z, et al. Among authors: collichio fa. J Immunother Cancer. 2022 Aug;10(8):e004417. doi: 10.1136/jitc-2021-004417. J Immunother Cancer. 2022. PMID: 36002183 Free PMC article.
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS, Alkallas R, Carroll SB, Caressi C, Zakria D, Patel NM, Trembath DG, Ezzell JA, Pegna GJ, Googe PB, Galeotti JP, Ayvali F, Collichio FA, Lee CB, Ollila DW, Gulley ML, Johnson DB, Kim KB, Watson IR, Moschos SJ. Karachaliou GS, et al. Among authors: collichio fa. BMC Cancer. 2022 Jan 5;22(1):38. doi: 10.1186/s12885-021-08908-z. BMC Cancer. 2022. PMID: 34986841 Free PMC article.
43 results